 This study aims to assess a fixed-dose regimen of activated prothrombin complex concentrate FEIBA VH, Baxter versus the variable, manufacturer recommended, dose regimen of inactivated prothrombin complex concentrate Kcentra, CSL Behring for reversal of warfarin-associated major hemorrhage. 